Clinical Trial Successes And Shifting Demographics Will Transform Oncology

Published
03 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$8.20
62.3% undervalued intrinsic discount
15 Aug
US$3.09
Loading
1Y
-5.2%
7D
-4.6%

Author's Valuation

US$8.2

62.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 31%

Shared on24 Apr 25
Fair value Decreased 24%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.

Shared on17 Apr 25

Shared on09 Apr 25